Pharmacia & Upjohn Takes $436M Charge In 1996

3 March 1997

Pharmacia & Upjohn took a charge of $36 million net of tax in 1996 fornon-recurring items which included merger costs and restructuring charges. Including the charge, the firm's net earnings for the year were $562 million, and earnings per share were $1.07. Excluding non-recurring items, net income was $998 million and EPS was $1.90.

Turnover achieved in 1996 was $7.18 billion, an increase of 3.3%. The firm said that sales were driven by performances of new products and marketing synergies. It was noted that the strengthening US dollar, particularly against certain currencies such as the yen, reduced 1996 sales by 2%.

In the fourth quarter of 1996, turnover was $1.94 billion, up 7.5%. Net earnings were $268 million before non-recurring items, and EPS was 51 cents. The quarter's non-recurring items amounted to $42 million or 8 cents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight